Citius Oncology

United States
Cranford, New Jersey, United States, 07016

Company profile

Citius Oncology company profile

Citius Oncology is a biopharmaceutical company that develops and commercializes oncology therapies. The company specializes in targeted therapies for cancer treatment, with a focus on immune-based approaches. The company recently gained FDA approval for LYMPHIR™, a therapy for relapsed or refractory cutaneous T-cell lymphoma.

Business identity

Contact email
[email protected]
Phone number
+1 908-967-6677
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Founded
2024-01-01, Year

Headquarters

Postal code
07016
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
3
Total equity funding
$36M
Last funding
Post IPO Equity / $18M / 2025-12-09
Last equity funding
Post IPO Equity / $18M
Articles
125
Exited on
2024-08-12

Founders and investors

No public relation records are available.